Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over
62 000 new cases occurred in men and women in 2015. The incidence continues to rise …

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …

Anaplastic thyroid cancer (ATC) is an extremely aggressive but rare form of thyroid
malignancy, making up only 1% to 2% of all thyroid cancers. 1 Although the incidence of …

Background: Therapeutic options for treating advanced or metastatic medullary thyroid
carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even …

Background: Anaplastic thyroid carcinoma (ATC) is an aggressive disease that requires
rapid diagnosis and multimodality treatment. Recent advances in targeted therapeutics have …

Background Treatment with radioactive iodine is effective for many patients with progressive,
locally advanced or metastatic, differentiated thyroid cancer. However, some patients …

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated,
medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and …

BACKGROUND Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies
in England and Wales. Differentiated thyroid cancer (DTC) accounts for≈ 94% of all thyroid …

Simple Summary Anti-VEGFR therapy has become a mainstay of treatment for thyroid
cancer across histological subtypes. However, the inhibition of this pathway is associated …

The development of orally active, multitargeted kinase inhibitors (MKIs) represents a
significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an …